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Chelation therapy has been the preferred method for the treatment of metal poisoning 
since the early 1900’s.  Several chelating agents have been used through the years for acute 
metal poisoning like ethylenediaminetetraacetic acid (EDTA) for lead (Pb), 2,3-
dimercaptopropano, British anti-Lewisite (BAL) for arsenic (As) or d-penicillamine for copper 
(Cu). However, the use of these chelators in the clinic has been limited due to the inconvenience 
of parenteral administration, intrinsic toxicity and redistribution of metals into the brain. Our lab 
has been focused on developing an orally bioavailable diethyl-ester analog of 
diethylenetriaminepentaacetic acid (DTPA), referred to as C2E2, in an attempt to overcome these 
limitations. Using basic pharmaceutics concepts, this dissertation characterizes the different 
polymorphic forms of C2E2 as well as assessing its metal binding efficiency both in in vitro and 
in vivo models.  
First, each of the three different C2E2 polymorphs produced under slightly different 
synthetic conditions were characterized. Each polymorph was evaluated by several spectroscopic 
techniques and different solubilities were established. Thermal characterization revealed 
different melting points and identified the most thermodynamically stable polymorph. 
Conversion between polymorphs was observed by means of mechanical stress and solvent-
mediated processes. The result of this investigation provides valuable information for future  
iv 
 
formulation and manufacturing processes of the compound. 
Next, the effect of chelation on the solubilization of ‘insoluble’ salts (IS) was explored. 
Chelation occurs between the interaction of the chelate and a “free” metal ion, but exogenous 
metals can accumulate in the form of precipitates. These precipitates are generally thought to be 
inaccessible to chelators in solution.  An alternative approach of using chelators as a means of 
dissolving IS was investigated. We showed that introducing chelators into the system increases 
the metal concentration in the bulk of both water and human plasma samples containing IS of 
different metals. These results offer insight for new targets in traditional chelation therapy.  
Finally, the efficacy of C2E2 was evaluated in vivo using a Pb contamination animal 
model. We showed that oral C2E2 resulted in a significant reduction in tissue Pb concentrations, 
particularly in male rats, with an efficacy of similar magnitude to current intravenous (I.V.) 
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CHAPTER 1: INTRODUCTION 
  
1.1  HEAVY METALS AND THEIR ROLE IN BIOLOGY 
  
An element which readily loses electrons to form cations (with the exception of 
hydrogen) is classified as a metal [1]. This is a useful definition to use from a physiological point 
of view since under biologically relevant conditions, metals exist mostly as solvated cations. A 
sub-section of this category are heavy metals. Although the criteria for defining a heavy metal 
varies by author and field [2], most definitions include a density greater than 5 g/cm3 (or 5x the 
density of water) and an atomic number greater than 20 [3-5]. We can further divide heavy 
metals into two categories: essential metals (e.g. iron (Fe), zinc (Zn) and copper (Cu)) and 
potentially toxic metals (e.g. arsenic (As), lead (Pb) and mercury (Hg)) [6]. 
Essential metals maintain various biochemical and physiological functions (e.g. catalytic 
cofactor, redox reactions [7,8]), but their concentrations are tightly regulated. Toxic metals can 
be harmful even in trace concentrations, but essential metals can also be noxious outside of the 
appropriate concentration threshold [9,10]. Their toxicity depends on several factors including 
the dose, route of exposure, and chemical species, as well as the age, gender, genetics, and 
nutritional status of exposed individuals [11,12]. 
Heavy metals are ubiquitous in nature and their physical properties make them excellent 
candidates for industrial, domestic, agricultural and medical applications, among others [13-15]. 




natural, mining, discharge of industrial effluents, urban runoff, sewage discharge, 
pesticides, and even medical procedures (Figure 1.1) [16]. 
 
Figure 1.1 Global production and emission of selected toxic metals 1850 - 1990. Figure from 
[13]. 
 
1.2  HEAVY METAL INTOXICATION 
The most well-known example of a heavy metal toxicity is lead poisoning. Lead 
poisoning, also termed “plumbism” from the Latin word for lead, plumbum, is of particular 
concern in children as it produces significant neurological deficiencies; long-term in both 
children and adults, it can also result in nephrotoxicity, reproductive dysfunction and 
cardiovascular diseases [17]. Interestingly, lead poisoning was only considered a problem within 




a sugar-free sweetener by ancient Romans [18]. Blood lead levels in the United States have been 
generally controlled within the last few decades, excluding the notorious water contamination in 
Flint, Michigan, with few cases being severe enough to warrant chelation [19]. Along with water 
contamination, industrial sources, exhaust from leaded gasoline and ingestion of lead-based 
paint, lead is also an issue for people with gunshot wounds, in which bullets or bullet fragments 
act as a depot for lead to continuously flow into the circulation. As such, lead poisoning is still a 
significant global health issue, particularly in warzones and developing countries with limited 
industrial regulations [20,21]. 
Cadmium is also becoming a significant contaminant in China, where it is deposited in 
the soil from atmospheric pollution, then taken up into rice crops [22]. Both cadmium and lead 
may contribute to cardiovascular disease, even at relatively low levels; their presence in tissues 
induce an inflammatory response, and if that tissue is a blood vessel wall under chronic 
inflammation, atherosclerotic cardiovascular disease could develop [23]. The link between these 
metal toxicants and cardiovascular disease was the hypothesis driving a recent large clinical trial 
in which the chelator ethylenediamine tetra-acetic acid (EDTA) was administered intravenously 
to high-risk patients to prevent further cardiovascular events (e.g. heart attack or death); the 
study produced significant positive results across all patients, even lowering the risk of 
cardiovascular disease by 50% in diabetic patients [24]. The results of the study are 
controversial, but it was well-defended by the investigators, leading to acceptance in a top 
medical journal and a follow-up clinical trial to further assess the relationship between the metals 





1.3  CHEMISTRY OF CHELATION 
Chelation therapy is the process of administering a drug (chelator) that will bind to a 
metal atom, creating a complex (chelate) that is eliminated from the body in an increased rate 
(relative to the unchelated metal) by natural physiologic processes. The word “chelation” is 
derived from the Greek “chele” meaning “claw” [26]. The analogy of a chelator as a claw is 
based on the tight constriction of a metal by the chelator molecule, which is usually attributed to 
the chelator’s strong nucleophilic moieties. 
The basis of chelation lies on coordination chemistry where we have a 2-center, 2-
electron covalent bond in which both electrons derive from the same atom [27]. Chelators, also 
known as ligands, are organic or inorganic compounds capable of forming two or more 
coordination bonds with a single metal center [28,29]. The term chelator itself has no direct 
relation to the number of available bonding sites, so a chelator can be bidentate (2 binding sites) 
or polydentate (more than 2). A chelating agent with a higher denticity (more atoms in the 
molecule that can bind to the metal) can occupy more coordination positions in the metal which 
will usually result in a more stable complex [26,28]. It is these multiple binding sites that provide 
more stability to the complex compared to one-site ligands of the same atom type (Figure 1.2) 
[30].  Mainly atoms like S, N and O function as ligand atoms in the form of chemical groups like 







Figure 1.2 Comparison of stability constants of nickel with six ammonia molecules (left) vs. 





A central metal ion is needed to complete the interaction. Some physiological metal 
cations of interest are: sodium (Na), magnesium (Mg), zinc (Zn) and transition metals like iron 
(Fe) and cobalt (Co). The resulting metal complex is referred to as a chelate. The chelate can 
have very different properties from its original ligand and metal; properties of charge, solubility, 
lipophilicity, redox potential, shape, and pH dependence can all be affected when the complex is 
formed [31,32]. Nevertheless, the stability of these complexes is going to depend on the 
properties of both of its predecessors. The stability constant of a complex, or how strong is that 
interaction is between ligand and metal, can be expressed as the ratio of the chelate concentration 
to the concentrations of the chelate components at equilibrium [33]: 
 
 = [][][] 
 
Where K is the stability constant, [ML] is the chelate concentration, [M] is the free metal 
concentration and [L] is the ligand concentration. This stability constant will depend on the 
atomic structure and size of the metal as well as denticity of the ligand. Figure 1.3 illustrates the 
relationship between the binding constants of different chelating agents (including DTPA) and 
several lanthanides; wherein binding strength increases with decreases in atomic radius [34]. The 
binding constant can also be used to determine which metals, have a lower binding affinity and 
can be displaced from the complex by other metals that have a higher binding affinity. There is 
an inverse relationship between ionic radius and binding affinity. In order to achieve the optimal 
chelation of a metal with a specific ligand, the properties of both metal and ligand need to be 






Figure 1.3 Binding constants for various aminopolycarboxylic acid chelators for 
lanthanides. Figure from [34]. 
 
In biological systems, chelators can be used for the purpose of mobilizing metals from 
tissues. These chelate complexes maintain their integrity and prevent the metal from being re-
absorbed during circulation. Then they can travel to the kidneys for excretion in the urine, and to 
the liver for excretion in the bile. The properties of the complex are not the same as the free 
ligand or free metal, therefore some crucial qualities necessary for an effective chelator are: 
1)   Appropriate pharmacokinetics:  in order to ensure that the ligand can move across 




2)   High affinity towards the metal of interest: this will ensure that a stable complex 
is formed as well as removing the metal from weaker-bound molecules. 
3)   Low toxicity and fast elimination: in order to prevent further complications. 
 
1.4  CHELATION AS A THERAPY FOR METAL TOXICITY 
 
The beginnings of chelation trace back to 1890’s with Werner’s theory of metal-ligand 
binding which established the basis for coordination chemistry and the discovery of 
arsphenamine, an arsenic containing complex, by Ehrlich as a treatment for syphilis [18,35]. The 
first of use of a chelator for metal removal came in 1941 when Kety and Leotonoff used citrate in 
an attempt to cure lead poisoning [36]. Their results showed a rapid decrease in both blood lead 
levels as well as symptomatic patients. While citrate might not be the most suitable candidate as 
a chelator because of its susceptibility to metabolism, it forged a new path for chelation as a 
treatment for acute metal toxicity.   
2,3-Dimercaptopropanol, or better known as British anti-Lewisite (BAL or dimercaprol), was 
the first chelator approved by the FDA specifically for metal poisoning [37]. Although it was in 
development during World War I to combat the arsenic based chemical gas Lewisite, production 
of BAL for clinical application was not ready until World War II. Ironically, Lewisite was never 
used in WWII because knowledge of the antidote became widespread. Currently BAL is only 
available by prescription as an intramuscular injection [38]. It has been approved by the FDA for 
treatment of arsenic (As), gold (Au) and mercury (Hg) poisoning as well as lead (Pb) poisoning 
if it is co-administered with edetate calcium disodium (Na2Ca-EDTA) [39]. In the 1960s, BAL 




currently the most prescribed chelating agent treatment in the USA [40]. A benefit of thiol-based 
chelators like BAL and DMSA is the ability to cross cell membranes and the ability to form 
disulfides with cysteine, adding carboxylic acid moieties to better bond metal cations. 
Aminocarboxylic acid chelators like EDTA and DTPA have also been used for clinical 
applications, though their use is more limited than thiol-based chelators because their broad 
metal-binding capacity also results in depleting essential trace metals [41]. This depletion can be 
countered by supplementation or formulating the chelators as complexes of trace metals (e.g., 
Ca-DTPA). EDTA is a weaker chelator than DTPA and is used more frequently, particularly 
when exposure to the metal contaminant has been prolonged and time is not of the essence (e.g., 
lead poisoning). DTPA, on the other hand, is used in cases where contamination was abrupt and 
a strong chelator is needed immediately to clear as much toxic metal as possible (e.g., nuclear 
fallout or accident) [38]. Aminopolycarboxylic acid chelators are also used for diagnostic 
applications for their seemingly irreversible binding ability. Metals like 99mTc and Gd are 
administered as DTPA- or DOTA-based complexes for various imaging applications, after which 
the complexes are cleared by renal filtration [41]. A big limitation of aminopolycarboxylic acids 
for chelation therapy is that they must be administered intravenously [42]. 
  
1.5  C2E2 
An orally bioavailable, synthetic di-ethyl ester analogue of DTPA, C2E2, was developed 
to address the limitations of other chelators [43]. The structure of C2E2 contains three carboxylic 
acids, three tertiary amines and two ester groups that distinguish it from DTPA (Figure 1.4). 
These two ethyl esters slightly increase the molecule’s permeability by increasing its 




4.90 to -2.10 for DTPA and C2E2, respectively [44]. As with most amphoteric molecules C2E2 
will be charged across the physiological pH range. The presence of charge on the zwitterions 
means that the solubility of C2E2 is high, however they correspondingly contribute to reduced 
oral absorption. This relatively low permeability coupled with its high aqueous solubility places 
this molecule in Biopharmaceutical Classification System (BCS) class III.   
 
 
Figure 1.4 Structure of DTPA and its analogue, C2E2. 
 
Single dose pharmacokinetic studies in Sprague-Dawley rats demonstrated that C2E2 is 
only minimally metabolized after administration [43]. The oral bioavailability was determined as 
29% compared to that of < 5% for DTPA in Sprague-Dawley rats [45]. Table 1.4. summarizes 













Melting Point 134.9 °C 220.0 °C 
Half-life (t1/2β) 1.1 hr 0.43 hr 
FPO 29% 5% 
tmax (po) 1 hr 1.55 hr 
Cmax (po) / Dose 24.15 (ng/mL)/(mg/kg) 2.06 x 10
-4 (ng/mL)/(mg/kg) 
Max tolerated dose 2000 mg/kg PO 59 mg/kg IV 
 
Table 1.4. Pharmacokinetic and toxicological profiles for DTPA and C2E2. 
The efficacy of C2E2 as an oral chelator was shown when administered to rats 24-hours after 
contamination with the transuranic element americium (Am) via intramuscular injection or 
inhalation [46]. A single oral dose of C2E2 induced significant improvement in total Am 
decorporation and reduced in the liver and skeletal Am burden. Thus, C2E2 appears to be an 
effective orally administered medical countermeasure for treating victims of nuclear accidents 
[47]. The convenience of an oral chelator can be exploited not only in situations of chemical 
warfare, but also for other instances of heavy metal contamination.  
 
1.6  SCOPE AND AIMS 
Heavy metal toxicity has proven to be a major global health threat. Although several 
adverse health effects have been known for many years, exposure to heavy metals continues, and 
is even increasing in some parts of the world, particularly in developing nations. The source of 
contamination can vary from environmental (e.g., lead) to a part of a medical procedure (e.g., 




For over 100 years chelation therapy has been the preferred method to treat heavy metal 
toxicity. Coordination chemistry can be used described the behavior of the chelating agent and 
reliable predictions can be made by studying the physical properties of these molecules. The first 
part of this work uses basic pharmaceutics concepts to further characterize C2E2 and its 
polymorphic forms. The results of these analysis will provide information relevant for 
formulation, pharmacokinetics and manufacturing.   
The rest of the work sought to characterize C2E2 as a candidate for non-nuclear heavy 
metal contaminations through both in vitro and in vivo assessments. Some of these metals may 
form insoluble salts after absorption into the systemic circulation and may deposit in various 
tissues and it is not known if chelation depletes insoluble metal forms. Additionally, established 
animal models of various metal contaminations can be used to determine the benefit of C2E2 in 
these settings.  
 
Aim 1: Identifying and characterizing the polymeric forms (PF) of C2E2. Physical and 
thermal and characterization of the solid-state of C2E2 is essential to designing a final clinical 
formulation.  
 
Aim 2: Determine the impact of C2E2 on the dissolution of insoluble salts. Here we 
conducted a study to determine if there was a relationship between the dissolution enhancement 
of inorganic salts that are insoluble in water and the presence of chelating agents in solution. 
 
Aim 3: Assess the ability of orally administered C2E2 to reduce the Pb content in various 




acetate in their drinking water undergo various treatment regimens. Lead retention will be 
compared in different tissues (kidney, bone, liver, brain) and will be used to asses C2E2’s 
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CHAPTER 2: PHYSICAL AND THERMAL CHARACTERIZATION OF THREE 
POLYMORPHIC FORMS OF C2E2 1 
 
2.1 INTRODUCTION 
Diethylenetriaminepentaacetic acid (DTPA) is an aminopolycarboxylic acid chelator that 
contains eight coordination sites which allow it to form stable complexes with different metal ions 
[1]. Currently, two salt forms (Ca-DTPA and Zn-DTPA) are approved by the FDA as intravenous 
(IV) injections for treatment of individuals contaminated with isotopes of plutonium (Pu), 
americium (Am), or curium (Cm) to increase their rates of elimination [2]. Nevertheless, chelation 
therapy with DTPA can often be a burden to the patient leading to diminished adherence due to 
the need of repeated intravenous administrations which requires a trained medical professional. 
An oral delivery route represents several advantages over the current IV treatment such as ease of 
administration (which in turns increases patient compliance), cost effectiveness, reduced sterility 
constraints, and flexibility of dosage form design [3]. To address this need, our laboratory has 
developed an orally bioavailable diethyl ester analog of DTPA, (C2E2). Substitution of two of the 
carboxylic groups with esters reduces the metal-binding coordination sites from eight to six but 
increases its lipophilicity as well as its bioavailability when compared to DTPA [4].  Previous work 
with C2E2 showed that it effectively enhances the elimination of 241Am after oral administration 
in a dog inhalation-contamination model and was well tolerated in rat toxicity studies at a dose of 
800 mg/kg for 10 days with no adverse effects [5]. The solid-state physical properties of this DTPA 
                                                 
1 This chapter previously appeared as an article in the journal of AAPS PharmSciTech. The original citation is as 
follows:  Sanchez, Carla Coste, et al. "Solid-State Characterization of Three Polymorphs of an Orally Available 




analog were investigated as part of a pre-formulation study in an effort to develop the most 
stable oral formulation of C2E2. 
Solid state characterization is an integral part of the pharmaceutical industry, from 
development and formulation, to dosage form [6]. The physical properties studied during 
characterization will impact the material’s bulk properties, processability, and physicochemical 
stability; therefore, these must all be investigated in order to have the desired product at the end of 
manufacturing [7,8]. Polymorphs can differ in solubility, dissolution rate, melting point, density, 
optical or electric parameters, and many other properties [9,10]. These properties have a profound 
effect on shelf life, chemical and physical stability, hygroscopicity, formulation, and processing 
properties, which in turn may impact bioavailability. This phenomenon is of particular importance 
in the pharmaceutical industry and new functional material design [11].  
In the case of C2E2, three polymorphic forms (PFs) were identified (referred as PF1, PF2, 
and PF3 in order of discovery), which present a distinct challenge in formulation development. 
The appearance of the polymorphs was directly related to the methods used to synthesize and 
purify C2E2. Because different polymorphic forms can have widely varying stabilities, 
solubilities, dissolution rates and thermal properties, an investigation of the physical and thermal 
characterization of the three C2E2 polymorphs was undertaken to determine which polymorph 
was the most appropriate for further formulation development and testing for its chelation 
efficiency with different metals. In this study, we present the three PFs discovered to date. The 
various solid forms are fully characterized by a range of analytical techniques, including 1H-NMR, 
solubility, Scanning Electron Microscopy (SEM), X-ray powder diffraction (XRPD), Fourier-
transform infrared (FTIR) spectroscopy, Raman spectroscopy (Raman), differential scanning 




the solid-state characterization and physicochemical properties of the three polymorphs of C2E2 
and allows for selection of a single PF for future studies.  
 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
All solvents used in synthesis and analysis were analytical grade and were purchased from Thermo 
Fisher Scientific (Fair Lawn, NJ) and Sigma Aldrich (St. Louis, MO).  
 
Methods 
2.2.2 Synthesis and generation of polymeric forms 
The synthesis of C2E2 has been previously reported by Huckle et al4 which produces PF1. 
Briefly, a condensation occurs by reacting DTPA, pyridine and acetic anhydride in 
dichloromethane (DCM) at 60°C for 6 hours to produce DTPA-bis anhydride (DTPA-BA). DTPA-
BA was esterified in the presence of ethanol and pyridine at room temperature to produce the final 






Scheme 2.1 Synthesis of diethyl ester analog of DTPA (C2E2). 
 
PF2 was synthetized in a scaled-up reaction carried out by Avista Pharma Solutions 
(Durham, NC). In the first step of this reaction, the solvent was changed from DCM to acetonitrile 
(ACN) and the esterification was carried out in a slurry of the DTPA-BA in ethanol and refluxed 
at 80°C for 1.5 hours with no pyridine.  The product was purified by hot filtration followed by 
gradual cooling overnight to 20°C and washing with tert-butyl methyl ether (MTBE). PF3 was 
also produced by Avista Pharma Solutions in an effort to improve the yield of the reaction and 
purify the product by taking the product of the above reaction (PF2) and forming a new slurry in 
ethanol. This was refluxed at 80°C for 6 hours to further esterify DTPA-BA that was detected in 
the production of PF2. After 6 hours of reflux, purification was carried out by hot filtration and 
the filtrate was cooled down to room temperature over 8 hours. This new slurry and second round 

















































2.2.3 Nuclear Magnetic Resonance (NMR)  
1H-NMR spectroscopy was performed using a Varian 400MR (Santa Clara, CA) 
spectrometer, with a 5mm AutoX Dual Broadband Probe (with Z-gradient). The software used for 
analysis was VnmrJ 3.2A (Agilent). All samples were prepared by dissolving the respective PF 
solid in dimethyl sulfoxide-d6 (DMSO-d6).
 
 
2.2.4 Solubility determination 
The apparent solubility of each polymorph was determined in triplicate by adding samples 
to deionized water in excess and left to stir; at various time-points (1, 2, 4, 12, 24 and 36 hours) a 
sample of supernatant was taken and filtered to remove undissolved solid. The concentration of 
the supernatant was then determined using a Prominence high performance liquid chromatography 
(HPLC) system (Kyoto, Japan) equipped with a Corona Ultra charged anion detector (CAD) 
(Sunnyvale, CA). A reverse phase gradient separation was performed using an Alltima C18 
column 250 x 2.1 mm2 internal diameter with 5 μm particle size at 40°C and a flow rate of 0.25 
mL/min. The mobile phases were composed of water with 0.1% trifluoroacetic acid (A), 
acetonitrile/isopropanol 2:1 (B). The mobile phase followed a linear gradient from 94:6 to 75:25 
over 14 min. The gradient was then increased for 0.5 min to achieve a ratio of 0:100 for 3.5 minutes 
followed by re-equilibration of the system at a 94:6 ratio for 6 min. The CAD analysis was 
performed at 25°C with nitrogen flow at 35.1 psi. 
 
2.2.5 Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC) 
TGA measurements were performed using a Mettler Toledo DSC/TGA calorimeter 




heating rate of 10°C/min under a nitrogen gas flow of 50 mL/min. The melting points and 
enthalpies of fusion of the three polymorphs were determined by differential scanning calorimetry 
(DSC) using a DSC Q2000 with a TA Instruments Refrigerated Cooling System 90 (TA 
Instruments, New Castle, DE). Powder samples weighing approximately 5 mg were placed in a 
hermetically sealed Tzero pan/lid system and heated from 25°C to 170°C at a rate of 2°C/min. 
After an isotherm of 170°C for 5 minutes, the samples were cooled to 25°C at a rate of 20°C/min.  
 
2.2.6 FT-Infrared Spectroscopy 
An Agilent CARY 650 FTIR spectrometer fitted with a Pike attenuated total reflectance 
(ATR) accessory and KBr beam splitter and DTGS detector was used to collect the spectra. A total 
of 16 scans at a resolution of 4 cm−1 were obtained. Agilent Pro software (version 4.2) was used 
to process the collected spectra.  
 
2.2.7 Raman Spectroscopy  
A Bruker Senterra Raman microscope (Billerica, MA) equipped with a 785 nm laser and 
20× objective was used to collect sample spectra at a spectral resolution of 4 cm−1. A total of 20 
co-additions with an integration time of 5 s was used for each measurement. OPUS software 
(Bruker Optic, version 7.2) was used to process the Raman spectra. 
 
2.2.8 X-ray powder diffraction (XRPD) 
A Rigaku Smartlab diffractometer (The Woodlands, TX) with Cu Kα radiation (40 kV, 40 




configuration. A step size of 0.02° with a scan rate of 4°/min was used for data collection at room 
temperature. 
 
2.2.9 Scanning Electron Microscopy (SEM) 
Scanning Electron Microscopy (SEM) analysis was performed on a Hitachi S-4700 Field 
Emission Microscope. Samples were prepared by depositing dry powders on double-stick carbon 
tape on an aluminum SEM sample holder. The samples were coated with a 10 nm layer of Gold-
Palladium (AuPd) alloy conductive coating. Operating conditions of Ultra High-Resolution mode 
(2 kV accelerating voltage, 10 microA beam current) and a working distance of 5 mm were 
maintained throughout the analysis.  
 
2.2.10 Polymorph Conversion and Stability 
Wet milling was performed by grinding a 1:1 mixture of the PF2 and PF3 solids in a 
ceramic mortar and pestle with 2 drops of ethanol for approximately 2 min. XRPD was performed 
between each of the eight grinding sessions and the relative intensity of a single diffraction peak 
unique to each PF was chosen for analysis. In a separate study, a slurry was formed by adding a 
1:1 mixture of PF2 and PF3 in 5 mL of ethanol and stirring overnight. After 24 hours, the slurry 
was filtered and the solid was dried for XRPD analysis. Separate slurries containing either PF2 or 








2.3 RESULTS AND DISCUSSION 
All three methods used to synthesize C2E2 yielded a white solid. The chemical structure 
of each of the polymorphs was confirmed by 1H-NMR (400MHz, d6 DMSO) δ 4.07 (4H, q), 3.53 
(4H, s), 3.41 (2H, s), 3.43 (4H, s), 2.92-2.80 (8H, m), 1.18 (6H, t) (Figure 2.1). Different degrees 
of peak splitting were observed in the peak located between 3.5-3.4 ppm due to differences in 
sample concentration. 
 
Figure 2.1 1H-NMR spectra comparison of C2E2 polymorphs, PF1 (red), PF2 (green) and 
PF3 (blue) in DMSO- d6. 
 
2.3.1 Solubility 
The apparent solubility of the three polymorphs was determined in triplicate in deionized 
water (final pH 2.4-2.6) and was measured after incubation for 1, 2, 4, and 24 hours at room 
temperature. There was no change in concentration observed at 4 or 24 hours compared to 2 hours. 
The apparent solubilities of PF1, PF2 and PF3 were 148.7 ± 1.7 mg/mL, 82.3 ± 6.8 mg/mL and 




determined by the solubility, where the least soluble compound will have the higher RTS.12,13 This 
driven by Gibbs free energy since the system will seek the lowest potential energy and solubility 
is a thermodynamic process.13,14 In terms of solubility PF1>PF2>PF3 which in turn determines 
that the RTS of PF3>PF2>PF1. 
 
2.3.2 Thermal Analysis (TGA and DSC) 
PF1 appears to be the least stable of the polymorphs, having the lowest melting point; PF2 
and PF3 have very similar thermal characteristics. The DSC curves of all three forms revealed a 
single endothermic event indicating the melting point (Figure 2); no other phase transitions were 
observed in the DSC measurements during single or cycle heating of any of the polymorphs. TGA 
confirmed the endotherms from the DSC as the melting points since no significant weight change 
was observed at the event temperature. PF1 melted at a temperature of 111.9°C (according to the 
onset of heat flow change) while PF2 and PF3 have closer, higher melting points at 137.6°C and 
134.9°C, respectively (Figure 2.2).  
 




The enthalpy of fusion (ΔHf) for each polymorph were determined to be 95.3 J/g, 104.9 J/g 
and 172.1 J/g, respectively. With this information we can determine the thermodynamic 
relationship between polymorphs. Any given two polymorphs can be related either monotropically 
or enantiotropically. In a monotropic system one of the polymorphs is stable over an entire 
temperature range while in an enantiotropic system, the transition temperature between the 
polymorphs is lower than the melting point and the free energy is equal between both 
configurations [16]. In the case of an enantiotorpic system the transition of two polymorphic 
modifications is endothermic, whereas for monotropic system it is exothermic [16]. According to 
the Heat of Fusion Rule (HFR), if the polymorph with the higher melting point has a lower heat of 
fusion, then the forms are enantropically related, else the forms are monotropically related.11 Thus, 
we determined that PF1 is monotropically related to both PF2 and PF3 (i.e., PF1 is less stable at 
any temperature compared to the other forms), and that PF2 and PF3 are enantropically related 
(i.e., stability of PF2 relative to PF3 is dependent on temperature).  
 
2.3.3 FTIR and Raman Spectroscopy 
The FTIR spectra showed that all three polymorphs exhibited a strong band at around 1729 
cm-1 arising from the carbonyl group vibrations. Some characteristic bands not clearly associated 
with any specific functional groups were observed at 1526, 1149 and 650 cm-1 for PF1, 1174, 1028 
and 736 cm-1 for PF2, and 1360, 1305 and 544 cm-1 for PF3 (Figure 2.3). The Raman diagnostic 
band stretching vibrations observed were as follows: 762, 825, 1026 and 1317 cm-1 for PF1, 584 
and 911 cm-1 for PF2 and 506, 608, and 1120 cm-1 for PF3. The differences in the bands allude to 




share a sharp band at around 825 cm-1 and another at about 1450 cm-1 that arises from the 
asymmetrical CH3 stretching vibrations (Figure 2.4). 
 





Figure 2.4. Raman spectra of C2E2 polymorphs, PF1 (red), PF2 (green) and PF3 (blue). 
2.3.4 XRPD 
The diffraction patterns of all three polymorphic forms were recorded at room temperature and 
differ significantly. Some unique peaks of PF1 were located at 7.8°, 18.8°, 21.0°, 22.5° and 35.5° 
± 0.2°; for PF2 at 8.1°, 11.9°, 18.1°, and 23.9° ± 0.2° and for PF3 at 5.3°, 20.5°, 28.7°, and 32.4° 
± 0.2° (Figure 2.5). Table 2.1 summarizes the unique characteristic peaks of each polymorph. The 
presence of unique peaks in each pattern indicates the existence of different arrangements and/or 
conformations of the molecules. 
  
 








Unique X-Ray diffraction peaks [2θ (deg)] 
1 
 
7.8, 12.6, 13.8, 14.2, 15.8, 18.8, 19.7, 21.0, 22.5, 24.3, 27.2, 28.7, 29.8, 




8.1, 11.9, 13.7, 15.3, 16.5, 18.1, 19.1, 21.2, 22.0, 23.9, 26.4, 29.1, 




5.3, 10.6, 15.6, 17.3, 18.9, 20.5, 21.4, 23.3, 24.5, 25.4, 26.9, 28.7, 31.2, 
32.4, 36.3 ± 0.2 
 
 
Table 2.1. Unique X-Ray diffraction peaks for each PF 
 
2.3.5 SEM 
SEM images clearly show the different crystal habits of all three polymorphs. Images 
confirm that all three solids are crystalline although with different structures (Figure 2.6): PF2 
possesses a triclinic crystal form whereas PF1 and PF3 are scaly in nature with PF3 showing 









Figure 2.6. SEM images displaying the different crystal habits of PF1 (a), PF2 (b) and PF3 
(c). 
 
2.3.6 Polymorphic Form Conversion  
To identify the most thermodynamically stable polymorph, two experiments were 
performed. PF1 had a much lower melting point and was never produced in the scaled-up batches, 
so it was not considered relevant to the mass production of C2E2 for clinical use; only conversions 
between PF2 and PF3 were studied.  Mechanical transformation of polymorphs has been 
previously reported [17]. The wet milling experiment demonstrated a decrease of intensity in the 
XRPD peak at 8.1° (characteristic of PF2) and an increase of intensity of the peak at 5.3° 
(characteristic of PF3) with each progressive milling step (Figure 2.7). This demonstrated that a 
mechanical force induced the conversion from the less stable polymorphic form of C2E2 (PF2) to 
the more stable polymorph (PF3). Similarly, the experiment in which a slurry of two C2E2 
polymorphs in ethanol was prepared showed complete solvent-mediated polymorphic 
transformation of PF2 to PF3 after 24 hours of stirring (Figure 2.8). No polymorphic 
transformations were observed in slurries of the individual polymorphs. In solvent mediated 
processes, the major contributor to this conversion is the difference in solubilities between the two 


















2.4  CONCLUSIONS 
PF1 has a lower melting point than PF2 and PF3, and is monotropically related to these 
forms, while PF2 and PF3 are enantropically related [19]. The higher value for the heat of fusion 
of PF3 suggests that this polymorph possesses the greatest thermodynamic stability of the three 
polymorphs. A disadvantage of the most thermodynamically stable form is that it is the least 
soluble, which was demonstrated by the solubility measurements. Conversion studies also showed 
that PF2 converts into PF3 under mechanical force as well as by solvent-mediated processes which 
further strengthens the conclusion that PF3 is the most thermodynamically stable polymorph.  For 
these reasons, PF3 was chosen for further testing and for use in in vivo safety and efficacy studies. 
Additional work will include crystal structure determination by single crystal diffraction or 
analysis of each powder as well as examining the relationship between bioavailability and its 
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Contamination with toxic metals, including lead (Pb), gadolinium (Gd) and transuranic 
radionuclides (e.g., plutonium and americium) is often associated with the deposition of phosphate 
or carbonate salts of these metals [1-3]. Using the USP definition of solubility, these deposits are 
considered ‘insoluble’, meaning that more than 10,000 parts of solvent (water) are required to 
solubilize 1 part of solute (solubility < 0.1 mg/mL). Decorporation of contaminant metals is 
achieved by administration of chelating agents, but it is generally assumed that chelation occurs 
with the exchangeable pool of the metal, i.e., protein-bound and loosely-complexed “free” metal 
ions [4]. The impact of chelation on insoluble salts (ISs) of the metals has not been determined 
and may have a significant role in the mechanism of metal decorporation. 
In environmental science, chelators are often employed for the mobilization of toxic metals from 
soils, where the metals are known to be present primarily as precipitates [5]. However, this process 
is usually aided by mild acidification, which would facilitate the dissolution of insoluble 
phosphates, carbonates and hydroxides [6]. Aminopolycarboxylic acids (e.g., EDTA and DTPA) 
have also been shown to dissolve calcium hydroxyapatite, the major component of bone, in simple 
media like water or buffers [7]. It is unknown if IS dissolution would happen rapidly enough in 
                                                 
1 This chapter was previously submitted as an article in the journal Trace Elements in Medicine and Biology. The 
original citation is as follows:  Sanchez, Carla Coste, et al. "Promoting Dissolution of Insoluble Salts in Plasma by 




vivo to be clinically relevant. Thus, we measured the dissolution of several insoluble salts by two 
chelators in physiologically-relevant media. Both chelators are clinically-relevant forms of DTPA: 
The Ca complex, which is used as a first-line agent in emergency chelation (Ca-DTPA) [8], and 
the orally-bioavailable di-ethyl ester of DTPA known as C2E2 [9]. 
 
3.2  MATERIALS AND METHDODS 
3.2.1  Materials 
Gadolinium carbonate (Gd2(CO3)3) was purchased from Santa Cruz Biotechnology 
(Dallas, TX). Gadolinium phosphate (GdPO4) was synthetized by boiling a solution of gadolinium 
oxide and dilute phosphoric acid as described by Kijkowska [10]; structure and purity were 
confirmed using Powder X-Ray Diffraction. Calcium phosphate (Ca3(PO4)2) was purchased from 
Sigma Aldrich (St. Louis, MO) and lead phosphate (Pb3(PO4)2) was purchased from Hairui 
Chemical (Zhejiang, China). Human plasma was purchased from Innovative Research (Durham, 
NC). C2E2 was synthesized by Avista Pharma Solutions (since acquired by Cambrex Corporation, 
Durham, NC) and Ca-DTPA was purchased from Mylan (Canonsburg, PA).  
 
3.2.2  Dissolution Kinetics 
The effect of chelating agents (C2E2 and Ca-DTPA) on the dissolution of insoluble salts 
of Gd, Ca and Pb was determined in triplicate at chelator concentrations of 0.5 mM. First, 20 mM 
chelator stock solutions were prepared by dissolving 45 mg of C2E2 in 5 mL of ultra-pure water, 
and separately diluting a 0.4 M solution of Ca-DTPA 20-fold. Sufficient quantity of the IS was 
added to 20 mLs of either water or human plasma for a final concentration of 0.5 mM creating the 




equilibrate. Then, each salt-media mixture was spun down at 14,000 rpm and the supernatant was 
sampled to measure a time 0 concentration; each mixture was then vortexed and triplicate samples 
(1.95 mL) were removed. After, 50 μL of the stock chelator solution, or water, was added to each 
sample to achieve a 0.5 mM chelator concentration. The chelator-salt-media mixtures were 
incubated at 37oC under mild agitation for 72 h. At pre-selected timepoints (1, 24, 48 and 72 h), 
the mixtures were centrifuged at 14,000 rpm and 200 μL of the supernatant were sampled and 
processed for ICP-MS analysis; after each centrifuge/sample process, the mixtures were vortexed 
and incubated under mild agitation until the next timepoint (Figure 3.1). 
 
3.2.3  Metal Quantification 
Plasma samples were digested with 70% nitric acid and then diluted with ultra-pure water 
for either Gd, Pb or Ca quantification by inductively coupled plasma mass spectrometry (ICP-MS) 
using an Agilent 7500cx ICP-mass spectrometer (Agilent Ind., Santa Clara, CA). Water samples 
were diluted in 2% nitric acid and analyzed in the same manner. The analysis was run in no-gas 
mode for Gd and Pb. Masses scanned were 156Gd and 208Pb. To account for variations in the 
isotopic composition between standards and samples, three isotopes of Pb (mass number = 206, 
207, and 208) were summed and reported as 208Pb.  115In and 193Ir served as the internal standards 
for Gd and Pb respectively. Calcium was analyzed in hydrogen mode to remove polyatomic 
interferences.  The collision/reaction cell was pressurized with hydrogen gas at a flow rate of 4.5 
mL/min.  The scanned masses included 44Ca and 45Sc which served as the internal standard.  Each 
data point is the mean of 5 replicate scans.  This instrument was tuned to maximize sensitivity 







Figure 3.1.  Sampling protocol (after time zero) to assess the dissolution of insoluble salts in plasma/water after chelators have 









3.2.4  Statistical Analysis 
The concentrations of Gd, Pb and Ca in each aliquot were analyzed by repeated measures 
two-way ANOVA followed by Sidak-adjusted multiple t-tests at each time point. Additional 
kinetic information was determined by fitting an exponential growth equation to the data (i.e., 
C∞*(1-exp(k*t)) + C0, where C0 and C∞ are the initial and final metal concentrations, respectively, 
and k is the first order dissolution rate constant). All analyses were done in Graphpad Prism v. 
6.05 (La Jolla, CA). 
 
3.3  RESULTS  
The rate of dissolution of IS was determined by measuring the change in metal 
concentration over time in plasma or water in the presence or absence of a chelating agent (C2E2 
and Ca-DTPA). The binding model fit well to the data for each IS and the regression results are 
summarized in Table 3.1 and Figures 3.2 and 3.3. In plasma, C2E2 increased the rate of dissolution 
of each IS. Ca-DTPA also showed this increase in all of the ISs except with Ca3(PO4)2. There are 
no overall differences between the dissolution rate constants (k) of each salt when comparing C2E2 
and Ca-DTPA. There are also no differences between fitted C0 and measured C0 values. Maximum 
binding efficiency was determined using C∞ and the only significant difference was for Ca3(PO4)2. 
In water, no significant differences were observed in k for any of the groups, but maximum binding 
(C∞) was significantly different between C2E2 and Ca-DTPA for Ca3(PO4)2 and Pb3(PO4)2. No 
difference was observed between fitted C0 and measured C0 values except for Gd2(CO3)3. The 
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R2 0.947 0.937 0.966 0.977 0.978 0.923 0.761 0.954 0.029 0.903 0.655 0.525 
Table 3.1.  The fit of the exponential binding equation to the supernatant metal concentration data. For the regression 
coefficients, data are presented as the estimates and 95% confidence intervals; the R2 values are unadjusted. In general, the equation fit 
well to the chelator data in both water and human plasma, except for the dissolution of calcium phosphate by Ca-DTPA when no net 
exchange can occur. The control (water) was able to fit most conditions, but each fit was poor (except for gadolinium phosphate in 
water) and the final concentrations (C∞) were not significantly different from the initial concentrations (C0). In some cases, the fitting 
























2 3 4 4 
C2E2/Control  
(N)a 
4 3 4 4 
Ca-DTPA/Control 
(N)a 
















1 3 4 1 
C2E2/Control  
(N)a 
4 3 4 4 
Ca-DTPA/Control 
(N)a 
4 0 0 4 
 
Table 3.2. Results for the model-free comparison of the supernatant metal concentration-time curves. The ANOVA results are 
from two-way repeated measures ANOVA, with the F-value for the interaction term; the significance (given by p-values) of the F-
value is based on 8 degrees of freedom for the numerator term and 24 for the denominator, based on three replicates per time-point 
and 5 total timepoints. 
a Number of timepoints that are significantly different from each other for the two curves by Sidak-adjusted t-tests. Since all curves 








Figure 3.2. Metal concentration in plasma supernatant. Solid lines represent the fit of an exponential binding equation. Statistical 








Figure 3.3. Metal concentration in water supernatant. Solid lines represent the fit of an exponential binding equation. Statistical 






3.4  DISCUSSION 
Using chelators to remove metals from a contaminated source (be it a body of water or a 
human body) has been extensively investigated; nevertheless, in most of these cases (if not all) the 
target metal is found in solution, whether in its free ionic form or bound to proteins [4]. In this 
study, we explored the alternative of using chelators as a new approach for the dissolution of IS to 
remove minerals from biological specimens. The results of this investigation demonstrate that in 
human plasma containing IS, both C2E2 and Ca-DTPA showed significant increase in metal 
concentration in the bulk solution, as a result of increased dissolution of the ISs.  
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where m represents the mass, t represents time, A represents the area of the solid, insoluble solute, 
D represents the diffusion coefficient of the solute in the solvent, d represents the thickness of the 
boundary layer, Cs represents the saturation solubility of the solute in the solvent, and Cb represents 
the concentration of the free metal in the bulk solution. By introducing a chelator that binds metals 
into the system, Cb is decreased by forming a metal-chelate complex (Figure 3.4.) This decrease 
in Cb causes an equilibrium shift which results in more solid dissolving in solution; this shift will 
favor dissolution until the chelator is saturated or the ratio of IS to chelated metal equals the ratio 







Figure 3.4. Equilibrium resulting in the dissolution of insoluble salts (IS) by the addition of a 
chelator. The dissolution process depends on the solubility of the compound (Cs) resulting in an 
equilibrium between the IS and the metal bulk concentration (Cb). When the chelator is 
introduced to the system, it binds metal ions reducing the concentration of free metal in solution, 
favoring further dissolution. A- represents the insoluble salt counter anion (e.g. phosphate). 
 
The addition of C2E2 or Ca-DTPA resulted in a 35-120% increase in solubilized metal 
plasma concentration. Only one combination of IS and chelator did not result in an increased metal 
concentration in water or plasma:  Ca-DTPA with Ca3(PO4)2. This is most likely attributable to the 
presence of calcium in the DTPA formulation. Any exchange of ions that occurs involving DTPA 
will have no net effect on the bulk concentration of the metal since the same metal (Ca) is being 
replaced. Thus, there is no driving force behind further dissolution than the slow innate process 
observed in the control. Different forms of DTPA, e.g., Zn-DTPA and Na2-DTPA, would not be 
expected to have the same limitation, but the slow exchange kinetics of Zn-DTPA [12] excluded 
it as a strong comparison to C2E2, and Na2-DTPA is not used clinically due to concerns of potential 
depletion of essential elements.  
The rate constants for the binding of metals by the chelators in plasma are associated with 




terminal elimination half-life of DTPA in man is 1.4 h [13] and the absorption-limited clearance 
of C2E2 observed in rats and dogs [14] suggests its terminal half-life would be significantly longer. 
Thus, clinically-significant dissolution of IS in vivo is very likely to occur during the mean 
residence time that chelators are in the body.  
 
3.5  CONCLUSIONS 
The chelators Ca-DTPA and C2E2 are effective at dissolving most insoluble salts of Ca, 
Gd and Pb in water and human plasma. For metal toxicities associated with deposition of insoluble 
salts, chelation therapy, in addition to binding soluble forms of the metals, may also enhance metal 
decorporation by dissolution and subsequent clearance of metals of those salts. The oral 
bioavailability of C2E2 as well as its longer half-life compared to DTPA make it attractive as a 
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4.1  INTRODUCTION 
 
Lead (Pb) is a naturally occurring element that has been widely used in a variety of 
consumer products including batteries, ceramics, cosmetics, gasoline, lead-based paints, pipes and 
plumbing materials [1]. However, Pb is also a neurotoxin that can accumulate in the body and 
cause long-term toxicity, especially in children under the age of six years old [2]. Although human 
lead exposure has decreased in the United States in the past few decades since the removal of lead 
from paint and gasoline [3], it continues to pose a serious public health concern due to its toxic 
effects on multiple organ systems. In children, attention deficit disorder and irreversible brain 
damage have been attributed to prolonged or high levels of exposure to Pb [4]. In adults, a 
chronically elevated blood lead levels (BLL) can result in hypertension, hyperuricemia, and gout 
[5]. Because Pb can interfere with multiple biochemical mechanisms, elevated BLL in adults can 
result in a number of negative outcomes including neurotoxicity, nephrotoxicity, reproductive 
dysfunction and cardiovascular complications [6,7].  
Current therapeutic approaches for the treatment of lead poisoning include chelation 
therapy that utilize injectable and orally-administered chelators, or a combination of the two, for 
moderate to severe intoxication depending on the BLL. Two FDA approved chelating agents for 
                                                 
1 This chapter was previously submitted as an article in the journal Trace Elements in Medicine and Biology. The 
original citation is as follows:  Sanchez, Carla Coste, et al. " Treatment of Lead Poisoning: Comparison of Orally 




the treatment of Pb poisoning are calcium disodium ethylenediaminetetraacetate (Ca-EDTA) and 
meso 2,3-dimercapto-succinic acid (DMSA), but both agents have limitations [8]. Ca-EDTA has 
a very low oral bioavailability and, thus, must be administered by intravenous (I.V.) infusion. This 
treatment can cause depletion of essential minerals by their enhanced urinary elimination. In 
addition, due to increased risks of lead encephalopathy and fatal cerebral edema when used at high 
doses, Ca-EDTA is safest and most effective when administrated at low concentrations through 
continuous infusion at slow rates [9]. However, because intravenous chelation therapy for lead 
poisoning generally requires repeated dosing and extended duration of therapy for five days or 
more [10], Ca-EDTA continuous infusion may be inconvenient and costly to treat large patient 
populations. On the other hand, DMSA is an orally-administered chelator, which is only approved 
for treatment of Pb poisoning in pediatric patients; its use in adults is off-label since the maximum 
tolerated dose has not been determined [11]. Because the dosing regimen of DMSA is based on 
pediatric parameters, the maximum recommended dose may be inadequate for adults. DMSA also 
has a lower affinity for binding Pb (log KA = 17.4) than EDTA (log KA = 18.0) [12]. 
Another agent that has been approved by FDA for treatment of radioactive heavy metal 
contamination is diethylenetriamine pentaacetic acid (DTPA) as either the calcium or zinc salt. 
DTPA has eight potential coordination sites that allow for avid binding to many metals and has a 
binding constant (log KA) for Pb that is 6.3-fold greater that EDTA and 21.8-fold greater than 
DMSA [13-15]. However, because it has a reported oral bioavailability is even less than of Ca-
EDTA [16], intravenous administration of DTPA in a clinical setting is required. As an 
alternative to these therapies, we evaluated the synthetic di-ethyl ester analogue of DTPA, 
designated as C2E2, for its ability enhance the elimination of Pb from rats that had been exposed 




of americium (Am) and plutonium (Pu) in contaminated animals after oral administration [17]. 
We also determined the concentrations of EDTA and C2E2 required to effectively bind 50% of 
Pb at a specified Pb concentration in human plasma.  
 
4.2  MATERIALS AND METHODS 
4.2.1  In vitro binding studies 
To quantify the binding of the chelating ligands (EDTA and C2E2) with Pb, a 
competitive binding experiment was carried out in human plasma. A stock solution of 30 mM Pb 
in water and 5 concentrations of the ligands in human plasma (1, 10, 100, 1,000, 10,000 μM) 
were prepared.  Samples consisted of 393 μL of blank/ligand containing plasma and 7 μL of the 
stock solution of Pb for a total of 400 μL with 0.52 mM of Pb. Each condition was run in 
triplicate. Samples were incubated for 60 minutes at 37°C with mild agitation. After incubation 
samples were transferred into an Amicon Ultra centrifugal filter with an Ultracel 3K membrane 
(Millipore, Billerica, MA) and centrifuged at 14,000 rcf for 30 min which resulted in the 
exclusion of the protein-bound Pb fraction. The filtrate was then transferred to a Pierce Strong 
Cation Exchange Spin Columns (Thermo Scientific, Rockford, IL) previously conditioned with 
an 0.8 M NaOH solution and centrifuged for 5 minutes at 2,000 rcf to separate the positively-
charged, free Pb ions from the ligand-bound Pb. Finally, to release free Pb from the column, two 
volumes of 1M HNO3 (400 μL each) was used to wash the column (Figure 4.1). The protein 
fraction was digested in 70% HNO3 for > 2 days. The digest as well as the other two fractions 
were diluted to a final HNO3 concentration of 2%. Inductively coupled plasma mass 






Figure 4.1. Experimental design for assessment of in vitro release of lead in plasma 
 
4.2.2.  Animals 
Male and female Sprague Dawley rats (Charles River, Wilmington, MA) were randomly 
divided into 4 groups with n = 4 per gender (16 total of each male and female). Animals were 
kept in individually ventilated cages with corn cob bedding in a room kept at 22 ± 2 °C with 
humidity between 30-70% and a 12-hour light-dark cycle with lights on from 7:00 - 19:00. Rats 
were given ad libitum access to distilled water and food (Teklad, Dublin, VA). After acclimating 
for one week, all rats were moved from distilled water to water containing 1000 ppm Pb in water 
bottles for 21 days. Rat weights were recorded 3x per week during this. On day 22, the rats were 
separated into 4 groups: 1 control group that received distilled water, and 3 treatment groups 
(oral C2E2 and DMSA, and I.V. Ca-EDTA) for 5 days. The general procedures for animal care 
and housing were conducted in accordance with the National Research Council for the Care and 




used in animal studies were reviewed and approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill.  
 
4.2.3.  Lead Loading and Treatment Protocols 
Fresh Pb-in-water solutions (1000 ppm) were prepared weekly using lead (II) acetate 
trihydrate (Sigma-Aldrich, St. Louis, MO). The water bottles were inspected every other day.  
C2E2 (Avista Pharmaceuticals, Durham, NC) was weighed and dissolved in distilled water for a 
final concentration of 10 mg/mL. DMSA (Sigma-Aldrich, St. Louis, MO) was weighed and 
dissolved in 5% NaHCO3 for a final concentration of 3 mg/mL. Ca-EDTA was prepared by 
dissolving equimolar quantities of EDTA (Acros Organics, Geel, Belgium) and calcium 
carbonate (Sigma-Aldrich, St. Louis, MO) in distilled water for a final concentration of 18 
mg/mL. The pH of the Ca-EDTA solution was adjusted with NaOH (Sigma-Aldrich, St. Louis, 
MO) to 6.5-7.5. The osmolarity was then  adjusted with NaCl (Sigma-Aldrich, St. Louis, MO) 
and measured with an Osmometer 3320 (Advance Instruments, Norwood, MA). 
Treatment groups were dosed daily by I.V. Ca-EDTA (25 mg/kg/day) or by adding the 
ligands (C2E2 and DMSA) to distilled water. The doses of C2E2 and DMSA delivered to the 
rats were determined by assuming an average water consumption rate of 100 mL/kg/day for rats 







4.2.4.  Organ harvest, sample preparation and ICP-MS analysis 
Three days after the last treatment dose, all animals were euthanized by CO2 asphyxiation 
followed by thoracotomy. Brain, femurs, kidney, liver, spleen and blood were collected from 
each animal. All tissue samples were weighed and digested in 5 mL of an acid solution (70% 
HNO3) for at least 2 days. Prior to digestion, livers were homogenized using a PowerGen™ 
High-Throughput Homogenizer (Fisher Scientific, Hampton, NH) and triplicate samples of ~ 
200 mg were used for digestion; all other organs were digested whole.  Digestion solutions were 
diluted to 2% HNO3 and analyzed for Pb content using an Agilent 7500cx ICP-mass 
spectrometer (Agilent Ind., Santa Clara, CA). To account for variations in the isotopic 
composition between standards and samples, three isotopes of Pb (mass number = 206, 207, and 
208) were summed and reported as Pb-208.  The analysis was run in no gas mode and used 
iridium (Ir) as an internal standard.  All masses (206Pb, 207Pb, 208Pb and 193Ir) were scanned for 
100 msec; each data point was reported as the mean of 5 replicate scans.  This instrument was 
tuned to maximize sensitivity while maintaining oxide and doubly charged species at or less than 
1%. 
4.2.5.  Statistical analyses 
The competitive binding studies were analyzed by fitting a binding equation that takes 
into account mass conservation of both the ligand and metal [19]: 
 =  ∙  1 + ! + " − #" − 1 + 2!" + 1 + !%& +c 
where Y is the fraction of Pb at a given concentration of ligand, X, Bmax is the maximum binding 
of Pb to the ligand and c is the minimum binding of Pb to ligand. Both the ligand and protein-




concentration of ligand necessary to effectively bind 50% of the Pb. The tissue Pb data from the 
animal study was analyzed by two-way ANOVA followed by Sidak-adjusted multiple 
comparisons. All analyses were performed in GraphPad Prism 6.05 (San Diego, CA).   
 
4.3  RESULTS 
4.3.1.  In vitro binding studies 
There was a ligand concentration-dependent decrease in protein-bound Pb which was fit 
well by the binding equation (Figure 4.2., Table 4.1.). The ligand-bound Pb data could not be fit 
by the equation (R2 < 0), so comparisons of the binding constant, r, for the two ligands were 
based on the protein-bound Pb data. Both ligands bound Pb with an affinity within the same 
order of magnitude, and the fitted constants (concentration where 50% of maximum binding 
occurs) were not significantly different [287 μM for C2E2 (95% CI = 130-443 μM) and 196 μM 











 Fraction Bmax r c R2 
C2E2 
Protein -0.899 287 1.02 0.966 
Ligand 0.862 283 -0.0192 0.964 
Ca-EDTA 
Protein -0.945 196 1.01 0.989 
Ligand -1.20 2.27E-20 1.48 -2.78 
 
Table 4.1. Regression results of in vitro binding studies. A binding equation was fit to the 
concentration dependents association of ligand and lead. The equation describes the maximum 
metal bound to ligand (Bmax), the minimum bound (c), and inflection point (r). The inflection 
point represents the ligand concentration where 50% of maximum binding occurs. The fit of the 









Figure 4.2. Binding of lead to C2E2 and EDTA in human plasma. A sigmoidal binding equation was fit to data in both fractions. 










4.3.2.  Animals 
The results of the in vivo study showed that there was a significant gender effect in Pb 
accumulation in the organs of control animals (Table 4.2). In general, females had 55% more 
accumulation of Pb in tissues, the greatest difference being in kidneys (65%) with femurs 
exhibiting the lowest difference with males (45%). As a result, statistical analyses for the treated 
animals were performed separately. For both males and females, all tissue Pb concentrations 
except female spleens and femurs were significantly affected by treatment (all ANOVA p < 
0.05) (Figure 4.2). In female rats, a significant difference in Pb reduction was observed between 
EDTA-treated and control groups in brain, kidneys and livers (adjusted p < 0.05 for all).  
 
Organ Males (Average ± 
SEM) 
Females (Average ± 
SEM) 
Female:Male  
Brain 0.065 ± 0.004 0.107 ± 0.006 1.6 
Liver 0.073 ± 0.002 0.12 ± 0.01 1.6 
Spleen 0.28 ± 0.02 0.43 ± 0.03 1.5 
Kidneys 0.61 ± 0.03 1.01 ± 0.06 1.7 
Femur 14.8 ± 0.7 22± 2 1.5 
 
Table 4.2. Average Pb concentrations in tissues (μg of Pb/g of tissue) in untreated control 






The only significant difference in Pb organ retention between the female C2E2-treated 
and control groups was in the kidneys (adj p < 0.0001). When comparing female C2E2-treated 
and EDTA-treated groups, C2E2 was significantly less effective at removing Pb from the brain 
and kidneys (both adj. P < 0.05). In males, significant differences between C2E2-treated or 
EDTA-treated groups and the control group were observed in the brain, femur, kidneys and liver 
(adj p < 0.01 for all). No significant difference was found in spleen Pb content between the 
control and all treatment groups in male rats, but C2E2 significantly reduced Pb to a greater 
extent than EDTA (adj p < 0.05). DMSA treatment was not associated with Pb reduction relative 
















Figure 4.3. Effect of different chelators on Pb concentrations in tissues. Data was analyzed by 
ordinary one-way ANOVA followed by Sidak-adjusted multiple comparisons. * p < 0.05; ** p < 
0.01; *** p < 0.001; **** p < 0.0001. The DMSA group contained various significant differences 
compared to control or other treatments, but the effects were minor or trivial (e.g. no difference 
from control, but different compared to other treatments), so when significant differences exist, the 




4.4  DISCUSSION 
The results of this investigation demonstrate that there is a significant reduction in Pb-
tissue burden following oral C2E2 or I.V. EDTA treatment of rats that had been contaminated with 
Pb. Ca-EDTA has long been the treatment of choice for Pb poisoning; these results demonstrate 
that, in males, C2E2 is equally as effective as EDTA in reducing Pb burden in all tissues examined 
except for the spleen, in which case neither treatment resulted in a significant reduction of Pb tissue 
burden. There is a clear difference between males and females, both in treatment effect and overall 
Pb tissue accumulation. In females, we observed on average a 55% increase in Pb accumulation in 
tissues when compared to the male counterparts (Table 4.2). We did not observe the same 
reduction of Pb when C2E2 was used in females except in the kidneys.  
The results of the in vitro binding experiment were consistent with expectations based on 
the number of coordination sites on C2E2 and EDTA available for metal binding. The in vitro 
results were mirrored by what was observed in the in vivo study. The concentration of Pb selected 
for the in vitro studies far exceeded normal plasma Pb concentrations in patients considered for 
chelation therapy; if ~1% of Pb in whole blood is in plasma [20], then at a concentration of 45 
μg/dL (the BLL above which interventional chelation therapy is indicated), the plasma 
concentration would be 55 nM. At lower concentrations of Pb in the assay used, C2E2 and EDTA 
did not bind Pb in a concentration-dependent manner that would fit the binding equation. Thus, a 
higher Pb concentration was selected for the in vitro binding studies which showed sigmoidal, 
concentration-dependent binding that could extrapolate to lower plasma Pb concentrations. The 
effective binding concentration, r, calculated for C2E2 and EDTA are dependent on the 
dissociation constants for the ligands to Pb and the concentration of Pb. They can be reduced by 




(i.e., 55 nM/0.54 mM), suggesting that both EDTA and C2E2 can effectively bind 50% of plasma 
Pb at a concentration of 23 nM in plasma (23 nM 55 nM/(0.54 mM*225 μM). Based on the known 
pharmacokinetics of EDTA and C2E2 in rats [21-22], this 23 nM target is a much more achievable 
concentration than the ~225 μM determined by the in vitro study. This conclusion is further 
supported by the ability of EDTA and C2E2 to remove Pb in male rats. 
The gender differences observed in the study are likely attributable to different 
pharmacokinetics of C2E2 in male and female rats. The delivery of C2E2 in the drinking water is 
comparable to a continuous infusion in which steady state concentration is dependent upon rate of 
delivery and drug clearance. In pre-clinical GLP safety-pharmacology studies, we observed that 
after exposure to oral C2E2 over a 28-day period, male rats had slightly reduced clearance of C2E2 
relative to female rats [23]. It is also possible that the males consumed more water disproportionate 
to their mass relative to the female rats. These two factors would result in a slightly higher steady 
state concentration of C2E2 and explain why significant reduction of tissue Pb burden in males 
was achieved but not in females. On average, C2E2-treated females had a lower Pb tissue burden 
than control animals; based on this pharmacokinetic consideration, we would expect significant 
reduction of Pb in organs if the C2E2 concentration in the water was increased. We also observed 
similar gender differences in americium decorporation studies with C2E2 [24].  
The lack of any effect of the ability of DMSA to reduce Pb tissue burden might be explained 
by the method of delivery, i.e., in the drinking water. Previous studies have shown the ability of 
DMSA to lower Pb tissue burden when delivered by oral gavage, which may allow for an increased 
maximum concentration than can be achieved by administering the dose slowly over the course of 
one day through the drinking water [25-26]. Achieving a higher concentration by oral gavage 




also benefit the Pb removal by C2E2, but since DMSA was being directly compared to C2E2 in 
this study, both treatments were administered via drinking water. This may have limited the 
amount of water the DMSA rats would tolerate drinking, leading to slight dehydration that could 
reduce reabsorption of DMSA in the renal tubules [27]. However, there were no changes in the 
body weight of the DMSA-treated animals that would suggest serious dehydration, but the lack of 
any effective reduction in tissue Pb by DMSA treatment suggests that the clearance of DMSA-
bound lead was limited. A comparison between C2E2 and DMSA both given by oral gavage 
against and untreated control would verify if dehydration-exacerbated renal reabsorption of DMSA 
explains some of the observed lack of efficacy in reducing Pb tissue burden. 
  
Figure 4.4. Body mass (g) for animals. Day 1 is when Pb was introduced to the animals in the 
drinking water. The dashed black line represents the start of chelator treatment on day 22, which 






4.5  CONCLUSIONS  
In vitro studies of the binding of Pb by C2E2 and EDTA in human plasma indicated that 
blood levels of these chelators could be achieved which would allow the binding of a sufficient 
amount of Pb for enhanced reduction of Pb tissue burden. In the animal model used in in vivo 
studies, orally-administered C2E2 was as effective as intravenously-administered Ca-EDTA in 
reducing the Pb tissue burden in male rats that had been contaminated with Pb in their drinking 
water, while orally-administered DMSA was ineffective. The cause of the pronounced difference 
C2E2 efficacy observed between male and female rats is likely due to gender-specific differences 
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CHAPTER 5: SUMMARY AND CONCLUSIONS 
 
 
The use of chelation in the setting of heavy metal intoxication has resulted in increased 
survival and quality of life for impacted patients, but the balance between the most effective 
treatment and the most convenient one is often tilted towards convenience. C2E2 is an effective 
chelator that also offers convenience over equally effective alternatives. The first test of C2E2 
for clinical application was for americium in simulated nuclear fallout models in rats and dogs, 
where non-toxic doses were determined beginning with in vitro binding assays. Here we 
expanded the potential role of C2E2 to additional metal toxicities. 
 
Throughout this dissertation, I sought to solve molecular pharmaceutical inquiries 
looking through the lens of my traditional chemistry background. In doing so the combined 
output from this research should provide several avenues for clinical application of C2E2, and 
hasten the final development of its pharmaceutical dosage form. Chapter two is a test to this 
exploring an often-overlooked part of the drug development process. Polymorph screening, 
selection, and control all determine the success of new drug discovery and development. With 
the advancements in understanding of solid-state chemistry, along with new analytical 
techniques; realization of crystal engineering and molecular level design of pharmaceutical 
solids with desired physicochemical properties are now closer. 
The third chapter of this thesis challenges the theory behind the long-standing assumption 




because it’s outside systemic circulation. We conducted a study to determine if there was 
a relationship between the dissolution enhancement of inorganic salts that are defined as 
‘insoluble’ (i.e., having an aqueous solubility less than 0.1 mg/mL) in water and in the presence 
of chelating agents in solution. The results showed that chelation therapy may be a successful 
approach for increasing the decorporation of insoluble toxic metal deposits, opening a new 
avenue of study in chelation therapy.    
Finally, we explore alternative treatments for lead poisoning, a global health problem. 
The recommended protocols for treatment of Pb poisoning have not changed much over the past 
20-25 years and the current standard of care is based on data generated decades ago using far-
from-optimized dosing schedules. The lack of investigational agents for lead toxicity seems to 
suggest that the issue with lead is “solved,” even though no chelation treatment is currently 
associated with prolonged reduction in blood lead levels or clinically significant reduction in 
neurological effects. The present studies suggest that new orally-bioavailable chelators may be a 
more effective approach to treating Pb poisoning and may be safer than current therapies in that 
it does not appear to induce redistribution of Pb to the brain. This is a critical factor as the 
association between Pb contamination and diminished cognitive function is well established. 
Prevention of Pb redistribution to the brain offers hope to the millions of children living in areas 











APPENDIX 1: EFFICACY OF C2E2 FOR GD REDUCTION TISSUE BURDEN 
INTRODUCTION 
The deposition of gadolinium (Gd) from Gd-based contrast agents (GBCAs) has been the 
focus of extensive research from clinicians and industry [1]. The concerns relate to the toxicity of 
the Gd if it is released from the contrast agent, based on known toxic effects from Gd salts (e.g., 
Gd-acetate) [2]. There is sufficient evidence that a subset of GBCAs are associated with the 
release of Gd from deposited GBCAs, which could be associated with toxicity. Indeed, agents 
such as gadodiamide, which has a high propensity to release Gd [3], are most strongly related to 
a GBCA toxicity in patients with poor renal function, nephrogenic systemic fibrosis (NSF) [4]. 
However, more recently some patients with adequate renal function who have received a variety 
of GBCA classes have presented with NSF-like symptoms [5,6]. 
In the setting of heavy metal deposition, chelation therapy is considered a standard of 
practice [7]. Relatively common examples include lead intoxication [8] and radionuclide 
contamination [9]. Patients are typically exposed to these contaminants through inhalation, 
ingestion or skin breakage; these chemical forms of contaminants are elemental, oxides or simple 
salts [10,11]. GBCAs are a unique source of contamination because they enter the body as 
chelates and apparently deposit as both chelates and released Gd, thus using chelators to remove 
chelate-delivered Gd would seem oxymoronic [12]. However, given the benefit of excess 
chelator in GBCA formulations in reducing Gd deposition and given that no non-chelator 
candidates to remove Gd are currently under investigation, it is necessary to determine if 




C2E2 may have potential benefits as a concomitant agent to prevent Gd deposition, or as 
a treatment to reverse Gd deposition. Thus, several different doing strategies were assessed in rat 
model of Gd deposition. 
METHODS 
Sprague-Dawley rats were given 1 mmol/kg doses of gadodiamide via tail vein daily over 
ten days (10 doses total). Rats were also given C2E2 by oral gavage (600 mg/kg) at various times 
relative to gadodiamide doses. In all studies, the negative control was water, and in several the 
positive control was 14 mg/kg Zn-DTPA given via tail vein. The various protocols are 
summarized in Figure A1.1. 
Urine Gd values were monitored by placing rats were placed in metabolic cages 24-hr 
before the first C2E2 dose and collecting urine daily with a cage washes. After CO2 
asphyxiation, blood, kidneys, spleen, liver, femur and brain were harvested in most studies. 
Analyses of tissues followed similar processing as described previously in Chapter 5. Tissues 
were digested whole in 70% nitric acid, except liver which was homogenized. Triplicate samples 
were digested. Digested tissues were added to sufficient water to reach a final concentration of 
2% nitric acid. Final samples were analyzed for Gd content with ICP-MS. 
Concentration data were analyzed by one-way ANOVA for comparisons of three groups and t-











In rats who were given a single dose of C2E2 by oral gavage three days after the last dose 
of gadodiamide, there was a significant increase in urine Gd excretion that was sustained for 
three days (Figure A1.2). However, there were no differences in tissue concentration of Gd a 
week after C2E2 dosing (Figure A1.3). 
 
Figure A1.2. Enhanced urine Gd excretion with C2E2. Significance (* p < 0.05, ** p < 0.01, 





Figure A1.3. Organ Gd following single C2E2 dose. 
 
To simulate delay between GBCA exposure and chelation, rats were given a 10 day 
washout between GBCA and chelation with 5 doses each of C2E2 by gavage or DTPA I.V. 
Neither chelator was associated with significantly elevated urine Gd or different organ Gd 
concentrations relative to control (Figures A1.4). Compared to the single chelator dose study, the 
non-significant increase in urine Gd for the DTPA group after a longer delay is substantially less 





Figure A1.4. Urine Gd excretion with chelation starting 10 days after the last GBCA dose. 
 
 






 To determine the risk of C2E2 to redistribute Gd deposition from the peripheral tissue 
into the brain, rats were sacrificed 24 hr after a dose of C2E2 by oral gavage or DTPA I.V. There 
was no difference in tissue Gd distribution at 24 h (Figure A1.6). 
 




To investigate the benefit of early treatment, rats were given gavage doses of C2E2 an 
hour before each GBCA dose or an I.V. dose of DTPA 15 min before each GBCA dose. Gd 
deposition in the liver and kidneys were significantly reduced by prophylactic C2E2 dosing 
(Figure A1.7). 
 
Figure A1.7. Tissue Gd concentrations with chelators given approximately concomitantly 
with each GBCA dose. C2E2 and DTPA were significantly better in the kidneys, but only C2E2 




































C2E2 in the drinking water of male rats did not significantly reduce Gd deposition (Figure A1.8). 
There were non-significant trends in the liver and spleen. 
 
Figure A1.8. C2E2 in the drinking water did not reduce tissue Gd burden. 
 
DISCUSSION 
It appears the unique biokinetics of GBCAs result in C2E2 being ineffective at 
significantly reducing Gd deposition. More prolonged treatment at a later timepoint may be more 
effective, but given the lack of tissue Gd reduction from Ca-DTPA in rats 7 weeks after a 
gadodiamide dose [13], C2E2 treatment would have to be extremely prolonged. The present 
studies demonstrate that the competition of chelators for Gd in the early post-injection period is 
simply too much to overcome with the altered pharmacokinetics of oral drugs (C2E2), or DTPA 
salts with slow exchange kinetics (Zn-DTPA) [14]. If C2E2 has a role in clearing retained Gd, it 
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